Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Darunavir

FDA-approved product (tablet, oral), marketed as Darunavir, Prezista.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Darunavir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Immunodeficiency disease
  • Infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Protease inhibitors
FDA pharmacologic class
Protease Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE10

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Darunavir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Darunavir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

    NCT06337032 · start 2024-08-27

    Registered record
    Registry ID
    NCT06337032
    Conditions
    HIV-1-infection
    Interventions
    F/TAF (High Dose Tablet); F/TAF (Low Dose Tablet); F/TAF (Lowest Dose Tablet); F/TAF (High Dose TOS); F/TAF (Low Dose TOS); F/TAF (Lowest Dose TOS); E/C/F/TAF; E/C/F/TAF (Low Dose); Cobicistat (High Dose); Cobicistat (Low Dose); Cobicistat (TOS); B/F/TAF (High Dose); B/F/TAF (Low Dose); B/F/TAF (High Dose TOS); B/F/TAF (Low Dose TOS); B/F/TAF (Lowest Dose TOS); 3rd ARV Agent; Nucleos(t)ide reverse transcriptase inhibitors (NRTI); ATV; DRV; Lopinavir Boosted with ritonavir (LPV/r)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-08-27
    Completion
    2034-03
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionF/TAF (High Dose Tablet); F/TAF (Low Dose Tablet); F/TAF (Lowest Dose Tablet); F/TAF (High Dose TOS) +17 more
    PhasePhase 4
    Registry statusRecruiting

  • A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

    NCT05729568 · start 2023-05-15

    Registered record
    Registry ID
    NCT05729568
    Conditions
    HIV-1 Infection
    Interventions
    Teropavimab; Zinlirvimab; Lenacapavir Tablet; Lenacapavir Injection; Antiretroviral Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-05-15
    Completion
    2030-12
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionTeropavimab; Zinlirvimab; Lenacapavir Tablet; Lenacapavir Injection +1 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

    NCT04518228 · start 2021-09-01

    Registered record
    Registry ID
    NCT04518228
    Conditions
    HIV; Tuberculosis
    Interventions
    Bictegravir (BIC); Tenofovir alafenamide (TAF); Long-acting injectable formulation of cabotegravir (CAB LA); Dolutegravir (DTG); Atazanavir/ritonavir (ATV/r); Darunavir/ritonavir (DRV/r); Lopinavir/ritonavir (LPV/r); Cobicistat; Ritonavir; First-Line TB Treatment; Second-Line TB Treatment; Doravirine (DOR)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2021-09-01
    Completion
    2025-07-10
    Enrolment
    205

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Tuberculosis
    InterventionBictegravir (BIC); Tenofovir alafenamide (TAF); Long-acting injectable formulation of cabotegravir (CAB LA); Dolutegravir (DTG) +8 more
    PhaseNot recorded
    Registry statusTerminated

  • Inflammation and Co-Infections in D²EFT

    NCT04183738 · start 2021-02-01

    Registered record
    Registry ID
    NCT04183738
    Conditions
    HIV-infection/Aids; Human Herpesvirus 4 Infections; Cytomegalovirus Infections; Human Herpesvirus 8 Infection; Human Papilloma Virus
    Interventions
    NRTIs; Darunavir; Ritonavir; Dolutegravir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2021-02-01
    Completion
    2022-12-19
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-infection/Aids; Human Herpesvirus 4 Infections; Cytomegalovirus Infections; Human Herpesvirus 8 Infection +1 more
    InterventionNRTIs; Darunavir; Ritonavir; Dolutegravir
    PhasePhase 4
    Registry statusWithdrawn

  • Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'

    NCT04653194 · start 2020-09-30

    Registered record
    Registry ID
    NCT04653194
    Conditions
    Human Immunodeficiency Virus
    Interventions
    Biktarvy; Symtuza
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-09-30
    Completion
    2023-07-31
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus
    InterventionBiktarvy; Symtuza
    PhasePhase 3
    Registry statusCompleted

  • Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19

    NCT04386447 · start 2020-09-01

    Registered record
    Registry ID
    NCT04386447
    Conditions
    Covid-19; Corona Virus Infection; SARS-CoV 2
    Interventions
    Oxytocin; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2020-09-01
    Completion
    2020-12-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid-19; Corona Virus Infection; SARS-CoV 2
    InterventionOxytocin; Standard of Care
    PhasePhase 2
    Registry statusWithdrawn

  • Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients

    NCT04475120 · start 2020-04-15

    Registered record
    Registry ID
    NCT04475120
    Conditions
    Covid19
    Interventions
    liposomal lactoferrin; SOC therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2020-04-15
    Completion
    2020-07-02
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19
    Interventionliposomal lactoferrin; SOC therapy
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Bioequivalence Study of GP30101 800 mg (GEROPHARM) Versus PREZISTA® 800 mg ("Jonson&Jonson", Russia)

    NCT04268472 · start 2019-06-06

    Registered record
    Registry ID
    NCT04268472
    Conditions
    Bioequivalence
    Interventions
    GP30101; Prezista®; GP30101; Prezista®
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-06-06
    Completion
    2019-09-06
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBioequivalence
    InterventionGP30101; Prezista®; GP30101; Prezista®
    PhaseNot applicable
    Registry statusCompleted

  • Raltegravir One Thousand Two Hundred vs Darunavir-cb in Immnunosupressed Patients: ROTDIP Study

    NCT03842488 · start 2019-04

    Registered record
    Registry ID
    NCT03842488
    Conditions
    HIV Infections
    Interventions
    Experimental: RAL QD; Active comparator: DRV/cb
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-04
    Completion
    2021-03
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionExperimental: RAL QD; Active comparator: DRV/cb
    PhasePhase 4
    Registry statusUnknown

  • The Late Presenter Treatment Optimisation Study

    NCT03696160 · start 2019-03-05

    Registered record
    Registry ID
    NCT03696160
    Conditions
    HIV/AIDS
    Interventions
    Biktarvy; Symtuza
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-03-05
    Completion
    2024-06-17
    Enrolment
    447

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV/AIDS
    InterventionBiktarvy; Symtuza
    PhasePhase 3
    Registry statusCompleted

  • Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant

    NCT03589040 · start 2018-09-25

    Registered record
    Registry ID
    NCT03589040
    Conditions
    HIV; Contraception
    Interventions
    Etonogestrel 68Mg Implant; rilpivirine; darunavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2018-09-25
    Completion
    2020-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Contraception
    InterventionEtonogestrel 68Mg Implant; rilpivirine; darunavir
    PhasePhase 2
    Registry statusUnknown

  • Dolutegravir and Darunavir Evaluation in Adults Failing Therapy

    NCT03017872 · start 2017-11-23

    Registered record
    Registry ID
    NCT03017872
    Conditions
    HIV Infections
    Interventions
    NRTIs; Dolutegravir; Darunavir; Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-11-23
    Completion
    2023-10-31
    Enrolment
    831

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNRTIs; Dolutegravir; Darunavir; Ritonavir
    PhasePhase 4
    Registry statusUnknown

  • Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients

    NCT03256422 · start 2017-09-07

    Registered record
    Registry ID
    NCT03256422
    Conditions
    HIV Infections
    Interventions
    Treatment discontinuation
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-09-07
    Completion
    2020-03-02
    Enrolment
    640

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTreatment discontinuation
    PhasePhase 3
    Registry statusCompleted

  • RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled Infection

    NCT04064632 · start 2017-02-01

    Registered record
    Registry ID
    NCT04064632
    Conditions
    HIV Infection
    Interventions
    Rilpivirine + darunavir/cobicistat
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-02-01
    Completion
    2019-11-30
    Enrolment
    1,609

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionRilpivirine + darunavir/cobicistat
    PhasePhase 4
    Registry statusUnknown

  • A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir

    NCT03198884 · start 2017-01-01

    Registered record
    Registry ID
    NCT03198884
    Conditions
    HIV-1-infection
    Interventions
    Darunavir 800 MG, Norvir 100 MG, Dolutegravir 50 MG
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-01-01
    Completion
    2018-05-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionDarunavir 800 MG, Norvir 100 MG, Dolutegravir 50 MG
    PhaseNot recorded
    Registry statusCompleted